Key result
A critical evaluation of the history of underrecognition of sunitinib's cardiac toxicity highlights the need for improved adverse event monitoring in future cancer therapies.
Why the study?
Does sunitinib cause underrecognized cardiac toxicity in cancer patients?
Does sunitinib cause underrecognized cardiac toxicity in cancer patients?
Highlights the historical underestimation of sunitinib-induced cardiotoxicity to improve future adverse event monitoring in cancer trials.
Sunitinib (Sutent; Pfizer, New York, NY) represents one of the most successful cancer therapies, with US Food and Drug Administration (FDA) approval for three malignancies and ongoing trials in more than 30 tumor types. It also represents an instructive example revealing how adverse events can be vastly underestimated. The purpose of this article is to critically evaluate the history of the underrecognition of the cardiac toxicity of sunitinib and to propose solutions to improve adverse event monitoring for future therapies.
No takes yet. Share an insight, caveat, or question.
Witteles et al. (2012) conducted a review in Cancer and cardiac toxicity. Sunitinib was evaluated. A critical evaluation of the history of underrecognition of sunitinib's cardiac toxicity highlights the need for improved adverse event monitoring in future cancer therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: